WO2006024777A1 - Derives de pyrrole, leur preparation et leur utilisation en therapeutique - Google Patents
Derives de pyrrole, leur preparation et leur utilisation en therapeutique Download PDFInfo
- Publication number
- WO2006024777A1 WO2006024777A1 PCT/FR2005/002015 FR2005002015W WO2006024777A1 WO 2006024777 A1 WO2006024777 A1 WO 2006024777A1 FR 2005002015 W FR2005002015 W FR 2005002015W WO 2006024777 A1 WO2006024777 A1 WO 2006024777A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- substituted
- unsubstituted
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to 4,5-diphenylpyrrole-2-carboxamide derivatives, their preparation and their therapeutic application.
- R 1 represents hydrogen or a (C 1 -C 4) alkyl
- R2 represents:
- a non-aromatic carbocyclic radical C3-C12 unsubstituted or substituted one or more times with a (Ci-C4) alkyl, hydroxyl, cyano, (C1-C4) alkoxy, or a group COR12 ⁇
- a benzothiophenyl an indolyl, said radicals being unsubstituted or substituted one or more times by (C 1 -C 4) alkyl group;
- a phenylalkylene group wherein the alkylene is (C1-C3), unsubstituted or substituted on the alkylene with one or more methyl, hydroxyl, hydroxymethyl, methoxy, methoxymethyl, a group COR 2> and unsubstituted on the phenyl or substituted on the phenyl by one or more identical or different substituents selected from a halogen atom or a (C 1 -C 4) alkyl, trifluoromethyl, (C 1 -C 4) alkoxy, trifluoromethoxy;
- a benzhydryl or benzydrylmethyl group . a group NR 1 QRI 1 - or R 1 and R 2 together with the nitrogen atom to which they are attached constitute:
- R 42 represents a (C 1 -C 4) alkyl, phenyl, benzyl, (C 1 -C 4) alkoxy group, a trifluoromethyl group or a NR 1 R 3 R 4 group;
- R 1 and R 4 each independently represent a hydrogen atom or a (C 1 -C 4) alkyl group or together with the nitrogen atom to which they are attached constitute a radical chosen from azetidinyl, pyrrolidinyl, piperazinyl and piperidinyl; or azepinyl;
- R 5 represents a (C 1 -C 4) alkyl or trifluoromethyl group; n represents 0, 1 or 2;
- Alk represents a (C 1 -C 4) alkyl group; as well as their salts, solvates and hydrates.
- the compounds of formula (I) may comprise one or more asymmetric carbon atoms. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including the racemic mixtures are part of the invention.
- the compounds of formula (I) may exist in the form of bases or addition salts with acids. These salts are advantageously prepared with pharmaceutically acceptable salts, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds of formula (I) are also part of the invention.
- the compounds according to the invention may also exist in the form of hydrates or solvates, namely in the form of combinations or combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention.
- R 1 represents hydrogen or a (C 1 -C 4) alkyl
- R2 represents:
- a non-aromatic C 3 -C 12 carbocyclic radical which is unsubstituted or substituted one or more times with a (C 1 -C 4) alkyl group; . 1,2,3,4-tetrahydronaphthalenyl-1 or -2;
- R 1 and R 2 together with the nitrogen atom to which they are attached constitute either a 4-piperazin-1-yl or 1,4-diazepan-1-yl radical by a phenyl or benzyl group; is a piperidin-1-yl radical or pyrrolidin-1-yl mono- or gem-disubstituted with phenyl, benzyl, (C 1 -C 4) alkyl, hydroxyl, (C 1 -C 3) alkanoyl, (C 1 -C 4) alkoxycarbonyl or ( Ci-C4) alkoxycarbonylamino; the phenyl or benzyl groups being unsubstituted or substituted one or more times with a halogen atom and / or a methyl group;
- R3, R4, R5, R6, R7, R8 are each independently hydrogen or halogen, (C1-C5) alkyl, (C1-C8) alkoxy, trifluoromethyl or a group S (O) n AIk;
- R9 represents a (C1-C4) alkyl group
- R10 represents a hydrogen atom or a methyl group
- Rl I is (C3-C (5) alkyl, phenyl or (C3-Cio) cycloalkyl, said phenyl and cycloalkyl are unsubstituted or substituted by one or more halogen atoms and / or groups (Ci-C4) alkyl;
- - or Rio and Rn together with the nitrogen atom to which they are attached form a heterocyclic radical, saturated or unsaturated, of 5 to 11 atoms, bridged or not, whether or not comprising a spiric carbon and optionally containing a second heteroatom selected O or N, said radical being unsubstituted or substituted one or more times by a hydroxyl, (C 1 -C 4) alkyl, (C 1 -C 4) alkoxycarbonyl group; a phenyl group unsubstituted or substituted by one or more halogen atoms or (C 1 -C 4) alkyl groups;
- alkyl group is meant a linear or branched radical, such as in particular: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl, the methyl group being preferred for (C1-C4) alkyl, tert-butyl, 2-methylbutyl-2,3,3-dimethylbutyl-2 being preferred for (C4-C10) alkyl.
- alkylene group is meant a linear divalent radical, methylene and ethylene being preferred.
- alkoxy group is meant a linear or branched radical, the methoxy group being preferred.
- halogen atom is meant a fluorine, chlorine, bromine or iodine atom; the fluorine, chlorine or bromine atoms being preferred.
- the non-aromatic C 3 -C 12 carbocyclic radicals include mono or polycyclic condensed or bridged radicals.
- Monocyclic radicals include cycloalkyls for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl; cyclohexyl and cyclopentyl being preferred.
- the fused, bridged or spiro di- or tricyclic radicals include, for example, norbornyl, bornyl, isobornyl, noradamantyl, adamantyl, spiro [5.5] undecanyl, bicyclo [2.2.1] heptanyl, bicyclo [3.2.1] octanyl; bicyclo [3.1.1] heptanyl.
- heterocyclic radical saturated or unsaturated, of 4 to 11 atoms, containing or not containing a second hetero atom such as O or N
- radicals such as morpholin-4-yl, piperidin-1-yl, piperazin-1-yl , pyrrolidin-1-yl, octahydrocyclopenta [c] pyrrol-2-yl, piperidin-1-yl and morpholin-4-yl being preferred.
- mono-nitrogenated heterocyclic radical from 5 to 7 atoms, is meant a radical such as piperidin-4-yl or pyrrolidin-3yl, the piperidin-4-yl radical being preferred.
- monooxygenated heterocyclic radical from 5 to 7 atoms, is meant a radical such as tetrahydrofuranyl, tetrahydro-2H-pyranyl, oxepanyl: tetrahydrofuranyl being preferred.
- monosulfur heterocyclic radical from 5 to 7 atoms, is meant a radical such as tetrahydrothiophenyl or tetrahydrothiopyranyl.
- heterocyclic heteroaromatic radical from 5 to 7 atoms, is meant a radical such as pyridyl, pyrrolyl, thiophenyl or furanyl.
- R 1 represents hydrogen and R 2 represents a group NR 1 oR 11 in which R 1 Q and R n together with the nitrogen atom to which they are attached constitute a radical; saturated heterocyclic of 5 to 11 carbon atoms, unsubstituted or substituted one or more times with a (C 1 -C 4) alkyl;
- R 1 and R 2 together with the nitrogen atom to which they are attached constitute a piperidin-1-yl radical which is gem-disubstituted with a phenyl, benzyl, pyrrolidin-1-yl or piperidin-1-yl group and cyano (C 1 -C 3) alkanoyl or aminocarbonyl; or R 1 and R 2 together represent a piperazin-1-yl group substituted in -4 with benzyl itself unsubstituted or substituted by a halogen atom; and / or R3, R4, R5, R8, Ry and Rg each independently represent a hydrogen atom, a halogen atom or a methoxy group;
- R 9 represents a (C 1 -C 4) alkyl group; as well as their salts, solvates and hydrates.
- R 1 represents hydrogen and R 2 represents a piperidin-1-yl radical or a (C 1 -C 3) alkylene substituted with a phenyl and a methoxy or methoxycarbonyl group;
- R 1 and R 2 together with the nitrogen atom to which they are attached represent a piperidin-1-yl radical which is gem-4-disubstituted by a phenyl, piperidin-1-yl group and by an acetyl, aminocarbonyl or cyano;
- R 1 and R 2 together represent a piperazin-1-yl group substituted in -4 with a benzyl which is itself unsubstituted or substituted by a halogen atom;
- Rg is 4-chloro or 4-methoxy and R3 and R4 are 2,4-dichloro or 2-chloro, R5, R7, Rg is hydrogen;
- R9 represents a methyl group; as well as their salts, their solvates and their hydrates
- the present invention also relates to a process for preparing the compounds according to the invention.
- R3, R4, R5, R6, R7, R8 and R9 are as defined for (I) with an amine of formula HNR1R2 (III) wherein R1 and R2 are as defined for (I).
- the compound thus obtained is converted into one of its salts or solvates.
- the acid chloride As functional derivative of the acid (II) it is possible to use the acid chloride, the anhydride, a mixed anhydride, a C 1 -C 4 alkyl ester in which the alkyl is straight or branched, a benzyl ester, an ester activated, for example the p-nitrophenyl ester, or the opportunely activated free acid, for example, with N, N-dicyclohexylcarbodiimide or with benzotriazol-1-yloxotris (dimethylamino) -phosphonium hexafluorophosphate (BOP) or benzotriazol-1-yloxotris- (pyrrolidino) phosphonium hexafluorophosphate (PyBOP).
- N, N-dicyclohexylcarbodiimide or with benzotriazol-1-yloxotris (dimethylamino) -phosphonium hexafluor
- the 1,3-oxazole-3-carboxylic acid chloride obtained by reaction of thionyl chloride with the acid of formula (II), can be reacted with an amine HNR1R2 in an inert solvent, such as a chlorinated solvent (dichloromethane, dichloroethane, chloroform, for example), an ether (tetrahydrofuran, dioxane for example), or an amide (N, N-dimethylformamide for example) under an atmosphere inert, at a temperature between 0 ° C and the temperature, in the presence of a tertiary amine such as triethylamine, N-methylmorpholine or pyridine.
- an inert solvent such as a chlorinated solvent (dichloromethane, dichloroethane, chloroform, for example), an ether (tetrahydrofuran, dioxane for example), or an amide (N, N-dimethylformamide for example)
- One variant consists in pre-preparing the mixed anhydride of the acid of formula (II) by reaction of ethyl chloroformate with the acid of formula (II), in the presence of a base such as triethylamine, and reacting it with an amine HNR4R2, in a solvent such as dichloromethane, under an inert atmosphere, at room temperature, in the presence of a base such as triethylamine.
- Substitution of the dihydropyrrole ring by a substituted phenyl group is carried out in stage d) by the action of a substituted phenylboronic acid of formula (VIII) in the presence of a palladium catalyst such as tetrakis (triphenylphosphine) Pd (0) , palladium (O) bisdibenzylidène acetone [Pd (dba) 2], tris (dibenzylideneacetone) dipalladium (0), Pd palladium (II) acetate [Pd (OCOCH 3) 2], dichloro (diphénylphos ⁇ hinoferrocène) Pd ( II) [PdC ⁇ dppfj, and in the presence of a base.
- a palladium catalyst such as tetrakis (triphenylphosphine) Pd (0) , palladium (O) bisdibenzylidène acetone [Pd (dba
- step e nitrogen protection by the tosyl group is removed by the action of a diamine such as DBU (1,8-diazabicyclo [5.4.0] undecene) simultaneously the pyrrole ring is aromatized.
- a diamine such as DBU (1,8-diazabicyclo [5.4.0] undecene) simultaneously the pyrrole ring is aromatized.
- step f) the nitrogen of the pyrrole is alkylated by the action of an alkyl iodide of formula R 9 I, then the ester of formula (X) is hydrolyzed in a basic medium to obtain the acid of formula (II) ).
- the subject of the present invention is also the compounds of formula: in which :
- R3, R4, R5, R8, R7, R8 are each independently of one another hydrogen, halogen, (C1-C8) alkyl, (C1-C8) alkoxy, trifluoromethyl, or group S (O) n AIk; - Ts represents a tosyl group;
- Alk is a (C 1 -C 4) alkyl group; n represents 0, 1 or 2.
- esters of formula (X) are described in the literature: methyl and ethyl esters of 4,5-diphenyl-1H-pyrrole-2-carboxylic acid are described in J. Chem. Research, synopses, 1977, 10,247; 1H-pyrrole-5- (4-methoxyphenyl) -4-phenyl-2-carboxylic acid ethyl ester is described in Tetrahedron
- the present invention also relates to the compound of formula:
- R3, R4, R5, R ⁇ , R7 and Rg each independently of one another represent a hydrogen or halogen atom, a (C 1 -C 6) alkyl, (C 1 -C 6) alkoxy group, trifluoromethyl or a group S (O) n Alk with the proviso that R3, R4, R5, R8, R7, Rg do not simultaneously represent hydrogen, and with the proviso that when Rg is a 4-methoxy group, R3, R4 R5, R7, Rg do not simultaneously represent hydrogen;
- Alk represents a (C 1 -C 4) alkyl group
- n 0, 1 or 2.
- the subject of the present invention is also the compounds of formula: in which :
- X represents a halogen atom, a hydroxyl group, (C 1 -C 4) alkoxy or benzyloxy;
- R3, R4, R5, R8, R7, R8 are each independently of one another a hydrogen or halogen atom, a (C1-C6) alkyl, (C1-C ( ) ) alkoxy group, trifluoromethyl or a group S (O) n AIk;
- R 9 represents a (C 1 -C 4) alkyl
- Alk represents a (C 1 -C 4) alkyl
- n 0, 1 or 2.
- the compounds of formula (IIa) may also exist in the form of salts. Such salts are part of the invention.
- Amines of the formula HNR 1 -2 ()) are known or prepared by known methods.
- the nuclear magnetic resonance spectra are recorded at 200 MHz in DMSO-d ⁇ .
- s singlet
- d doublet
- t triplet
- m massive
- mt multiplet
- se expanded singlet
- dd doublet of doublet.
- the compounds according to the invention are analyzed by LC / UV / MS coupling (liquid chromatography / UV detection / mass spectrometry).
- the molecular peak (MH) and the retention time (tr) are measured in minutes.
- a symmetry C18 column of 2.1 ⁇ 50 mm, 3.5 ⁇ m, is used at 30 ° C., flow rate 0.4 ml / minute.
- the eluent is composed as follows:
- solvent A 0.005% trifluoroacetic acid (TFA) in water at pH 3.15;
- solvent B 0.005% of TFA in acetonitrile.
- the eluent is composed as follows:
- Solvent A 0.025% TFA in water
- UV detection is performed by an iodine bar detector between 210 and 400 nm and ESI positive mass detection.
- the crude is solubilized in dichloromethane and the organic phase is washed successively with a saturated aqueous solution of KHSO4 then K2CO3.
- the organic phase is dried over magnesium sulphate and then filtered and finally concentrated to obtain 5.18 g of the expected compound.
- the compounds of formula (I) described in Table 2 are prepared by combinatorial chemistry according to the method described below: the carboxylic acids of formula (III) are dissolved in DMF at a concentration of 0.25M in the presence of 3 equivalents of DIPEA. In each well of 2 ml, 120 ⁇ l of this solution and 120 ⁇ l of a solution of TBTU in DMF at the concentration of 0.25M are placed. 300 ⁇ l of a solution containing the amine of formula (III) in DMF at a concentration of 0.1M and 3 equivalents of DIPEA are added to each well. The plates are stirred at RT for 16 hours and then evaporated.
- the products formed are dissolved in each well with 500 ⁇ l of AcOEt, 400 ⁇ l of 0.1M Na 2 CO 3 are added and the plates are shaken. After decantation 430 .mu.l of aqueous phase are discarded and 300 .mu.l of 5% NaCl are added and the plates are stirred. 350 ⁇ l of aqueous phase are then discarded and the residues are analyzed by LC / UV / MS (MS5 conditions).
- Et, Me, nPr, tBu respectively mean ethyl, r ⁇ ethyl, n-propyl and tert-butyl.
- the compounds of formula (I) have a very good in vitro affinity (IC50 ⁇ 5.10 M) for CB cannabinoid receptors, under the experimental conditions described by M. Rinaldi-Carmona et al. (FEBS Letters, 1994, 350, 240- 244).
- the toxicity of the compounds of formula (I) is compatible with their use as a medicament.
- the invention relates to medicaments for human or veterinary medicine which comprise a compound of formula (I), or a solvate or a hydrate of the compound of formula (I).
- the compounds according to the invention can be used in humans or animals, in the treatment or prevention of diseases involving cannabinoid CB 1 receptors.
- the present invention relates to the use of a compound of formula (I), or a salt thereof, solvates or hydrates which are pharmaceutically acceptable, for the preparation of medicaments intended to treat or to prevent diseases involving cannabinoid receptors CBj.
- the compounds of formula (I) are useful as psychotropic drugs, especially for the treatment of psychiatric disorders including anxiety, depression, mood disorders, insomnia, delusional disorders , obsessive-compulsive disorder, psychosis in general, schizophrenia, attention deficit and hyperactivity disorder (ADHD) in hyperkinetic children (BDM), and the treatment of disorders related to the use of psychotropic substances, particular in the case of an abuse of a substance and / or substance dependence, including alcohol dependence and nicotine addiction.
- psychiatric disorders including anxiety, depression, mood disorders, insomnia, delusional disorders , obsessive-compulsive disorder, psychosis in general, schizophrenia, attention deficit and hyperactivity disorder (ADHD) in hyperkinetic children (BDM)
- ADHD attention deficit and hyperactivity disorder
- BDM hyperkinetic children
- the compounds of formula (I) according to the invention can be used as medicaments for the treatment of migraine, stress, psychosomatic diseases, panic attacks, epilepsy, movement disorders , especially dyskinesias or Parkinson's disease, tremors and dystonia.
- the compounds of formula (I) according to the invention can also be used as medicaments in the treatment of memory deficits, cognitive disorders, in particular in the treatment of senile dementias, of Alzheimer's disease, as well as in the treatment of disturbances of attention or alertness.
- the compounds of formula (I) may be useful as neuroprotective agents, in the treatment of ischemia, head trauma and the treatment of neurodegenerative diseases: including chorea, Huntington's chorea, Tourrette's syndrome.
- the compounds of formula (I) according to the invention can be used as medicaments in the treatment of pain: neuropathic pain, acute peripheral pain, chronic pain of inflammatory origin.
- the compounds of formula (I) according to the invention can be used as medicaments in the treatment of appetite disorders, palatability (for sugars, carbohydrates, drugs, alcohols or any appetizing substance) and / or conduits. for the treatment of obesity or bulimia, as well as for the treatment of type II diabetes or non-insulin-dependent diabetes mellitus and for the treatment of dyslipidemia, metabolic syndrome.
- the compounds of formula (I) according to the invention are useful in the treatment of obesity and the risks associated with obesity, in particular cardiovascular risks.
- the compounds of formula (T) according to the invention can be used as medicaments in the treatment of gastrointestinal disorders, diarrheal disorders, ulcers, vomiting, bladder and urinary disorders, endocrine disorders, cardiovascular disorders, hypotension, hemorrhagic shock, septic shock, chronic cirrhosis of the liver, chronic hepatic encephalopathy, asthma, chronic bronchitis and bronchitis.
- chronic obstructive pulmonary disease Raynaud's syndrome, glaucoma, fertility disorders, inflammatory phenomena, diseases of the immune system, especially autoimmune and neuroinflammatory diseases such as rheumatoid arthritis, reactive arthritis, diseases causing demyelination, multiple sclerosis, infectious and viral diseases such as encephalitis, stroke as well as edicaments for cancer chemotherapy and for the treatment of Guillain-Barré syndrome and for the treatment of bone diseases and osteoporosis.
- autoimmune and neuroinflammatory diseases such as rheumatoid arthritis, reactive arthritis, diseases causing demyelination, multiple sclerosis, infectious and viral diseases such as encephalitis, stroke as well as edicaments for cancer chemotherapy and for the treatment of Guillain-Barré syndrome and for the treatment of bone diseases and osteoporosis.
- the compounds of formula (T) are particularly useful for the treatment of psychotic disorders, in particular schizophrenia; Attention Deficit Hyperactivity Disorder (ADHD) in hyperkinetic children (BDM) for the treatment of appetite and obesity disorders, for the treatment of memory and cognitive deficits; for the treatment of alcohol dependence, nicotine addiction, ie for alcohol withdrawal and smoking cessation; and for the treatment of dyslipidemias, the metabolic syndrome.
- ADHD Attention Deficit Hyperactivity Disorder
- BDM hyperkinetic children
- BDM hyperkinetic children
- alcohol dependence for the treatment of alcohol dependence, nicotine addiction, ie for alcohol withdrawal and smoking cessation
- dyslipidemias the metabolic syndrome.
- the compounds of formula (I) according to the present invention are useful in the treatment and prevention of appetite disorders, metabolic disorders, gastrointestinal disorders, inflammatory phenomena, diseases of the immune system.
- the present invention relates to the use of a compound of formula (I), of its pharmaceutically acceptable salts and of their solvates or hydrates for the treatment of the disorders and diseases indicated above.
- the compound according to the invention is generally administered in dosage unit.
- Said dosage units are preferably formulated in pharmaceutical compositions in which the active ingredient is mixed with a pharmaceutical excipient.
- the present invention relates to pharmaceutical compositions containing, as active principle, a compound of formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof.
- the compound of formula (I) above and its pharmaceutically acceptable salts or solvates may be used at daily doses of 0.01 to 100 mg per kg of body weight of the mammal to be treated, preferably at daily doses of 0, 02 to 50 mg / kg.
- the dose may preferably vary from 0.05 to 4000 mg per day, more particularly from 0.1 to 1000 mg per day depending on the age of the subject to be treated or the type of treatment, namely prophylactic or curative.
- these assays are examples of average situations, there may be special cases where higher or lower dosages are appropriate, such assays also belong to the invention.
- the dosage appropriate to each patient is determined by the physician according to the mode of administration, the age, the weight and the response of said patient.
- the active ingredient can be administered in unit dosage form, in admixture with conventional pharmaceutical carriers, animals and humans.
- suitable unit dosage forms include oral forms such as tablets, capsules, powders, granules and oral solutions or suspensions, sublingual and oral forms of administration, aerosols, dosage forms topical, implants, forms of subcutaneous, intramuscular, intravenous, intranasal or intraocular administration and rectal administration forms.
- the active principle is generally formulated in dosage units containing from 0.05 to 1000 mg, advantageously from 0.1 to 500 mg, preferably from 1 to 200 mg of said active ingredient per unit of dosage for daily administrations.
- a unitary form of administration of a compound according to the invention in tablet form may comprise the following components:
- the dose of active ingredient administered per day can reach 0.01 to 100 mg / kg, in one or more doses, preferably 0.02 to 50 mg / kg.
- the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.
- the present invention also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention, or hydrates or solvates.
- a compound of formula (I) may be combined with another active ingredient chosen from one of the following therapeutic classes:
- an AT1 receptor antagonist of angiotensin II alone or in combination with a diuretic an AT1 receptor antagonist of angiotensin II alone or in combination with a diuretic
- a beta-blocker alone or in combination with a diuretic or a calcium antagonist; an antihyperlipidemic agent or an antihypercholesterolemic agent;
- compositions containing in combination a compound of formula (I) and another active principle chosen from one of the following therapeutic classes:
- an AT1 receptor antagonist of angiotensin II alone or in combination with a diuretic or a calcium antagonist
- beta-blocker alone or in combination with a diuretic or a calcium antagonist
- an antihyperlipidemic agent or an antihypercholesterolemic agent an antihyperlipidemic agent or an antihypercholesterolemic agent
- angiotensin II AT1 receptor antagonist is meant a compound such as candesartan cilexitil, eprosartan, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan, each of these compounds may itself be associated with a diuretic such as hydrochlorothiazide.
- inhibitor of the conversion enzyme is meant a compound such as alacepril, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril, zofenopril, each such compounds may itself be associated with a diuretic such as hydrochlorothiazide or indapamide or a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil.
- a diuretic such as hydrochlorothiazide or indapamide
- a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil.
- calcium antagonist is meant a compound such as amlodipine, aranidipine, benidipine, bepridil, cilnidipine, diltiazem, efonidipine hydrochloride ethanol, fasudil, felodipine, isradipine, lacidipine, lercanidipine hydrochloride, manidipine, mibefradil hydrochloride, nicardipine, nifedipine, nilvadipine, nimodipine, Nisoldipine, Nitrendipine, Terodiline, Verapamil.
- beta-blocker is meant a compound such as acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevololol, bisoprolol, bopindolol, bucumolol, bufetolol, bunitrolol, butofilolol, carazolol, cardolol, carvedilol, cloranolol, epanolol, esmolol.
- antihyperlipidemic or antihypercholesterolaemic is meant a compound selected from fibrates such as alufibrate, beclobrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate; statins (HMG-CoA reductase inhibitors), such as atorvastatin, fluvastatin sodium, lovastatin, pravastatin, rosuvastatin, simvastatin, or a compound such as acipimox, aluminum nicotinate, azacosterol, cholestyramine, dextrothyroxine, meglutol, niceritrol, nicoclonate, nicotinic acid , beta-sitosterin, tiadenol.
- statins HMG-CoA reductase inhibitors
- atorvastatin fluvastatin sodium,
- antidiabetic means a compound belonging to one of the following classes: sulfonylureas, biguanidines, alpha glucosidase inhibitors, thiazolidinedione, methaglinides, such as acarbose, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide , glimepiride, glipidide, gliquidone, glisoxepide, glybuzole, glymidine, metahexamide, metformin, miglitol, nateglinide, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, voglibose.
- sulfonylureas biguanidines
- alpha glucosidase inhibitors such as acarbose, aceto
- anti-obesity agent a compound such as amfepramone, benfluorex, benzphetamine, indanorex, mazindole, mefenorex, methamphetamine, D-norpseudoephedrine or another CB i cannabinoid receptor antagonist.
- the subject of the present invention is a pharmaceutical composition containing in combination a compound of formula (I) and an AT 1 receptor antagonist of angiotensin II, in particular irbesartan, losartan or valsartan.
- the compound of formula (I) and the other associated active ingredient can be administered simultaneously, separately or spread over time.
- Extended use over time is understood to mean the sequential administration of the first compound of the composition according to the invention, included in a pharmaceutical form, then, of the second compound of the composition according to the invention, included in a form pharmaceutical industry.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05796087A EP1781636A1 (fr) | 2004-08-09 | 2005-08-02 | Derives de pyrrole, leur preparation et leur utilisation en therapeutique |
AU2005279086A AU2005279086A1 (en) | 2004-08-09 | 2005-08-02 | Pyrrole derivatives, their preparation and their therapeutic use |
CA002576717A CA2576717A1 (fr) | 2004-08-09 | 2005-08-02 | Derives de pyrrole, leur preparation et leur utilisation en therapeutique |
EA200700179A EA012726B1 (ru) | 2004-08-09 | 2005-08-02 | Производные пиррола, их получение и их применение в терапии |
MX2007001383A MX2007001383A (es) | 2004-08-09 | 2005-08-02 | Derivados de pirrol, su preparacion y su utilizacion en terapeutica. |
JP2007525320A JP2008509202A (ja) | 2004-08-09 | 2005-08-02 | ピロール誘導体、その調製及びその治療上の使用 |
BRPI0514235-0A BRPI0514235A (pt) | 2004-08-09 | 2005-08-02 | derivados de pirrol, o respectivo preparo e a respectiva utilização em terapêutica |
IL180867A IL180867A0 (en) | 2004-08-09 | 2007-01-22 | Pyrrole derivatives, their preparation and their therapeutic use |
US11/625,616 US7381727B2 (en) | 2004-08-09 | 2007-01-22 | Pyrrole derivatives, their preparation and their therapeutic use |
NO20071209A NO20071209L (no) | 2004-08-09 | 2007-03-05 | Pyrrolderivater, deres fremstilling og deres terapeutiske anvendelse |
US12/102,412 US7879902B2 (en) | 2004-08-09 | 2008-04-14 | Pyrrole derivatives, intermediates therefor, preparation and therapeutic use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0408773 | 2004-08-09 | ||
FR0408773A FR2874012B1 (fr) | 2004-08-09 | 2004-08-09 | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/625,616 Continuation US7381727B2 (en) | 2004-08-09 | 2007-01-22 | Pyrrole derivatives, their preparation and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006024777A1 true WO2006024777A1 (fr) | 2006-03-09 |
Family
ID=34947270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/002015 WO2006024777A1 (fr) | 2004-08-09 | 2005-08-02 | Derives de pyrrole, leur preparation et leur utilisation en therapeutique |
Country Status (20)
Country | Link |
---|---|
US (2) | US7381727B2 (fr) |
EP (1) | EP1781636A1 (fr) |
JP (1) | JP2008509202A (fr) |
KR (1) | KR20070054649A (fr) |
CN (1) | CN101014588A (fr) |
AR (1) | AR050447A1 (fr) |
AU (1) | AU2005279086A1 (fr) |
BR (1) | BRPI0514235A (fr) |
CA (1) | CA2576717A1 (fr) |
EA (1) | EA012726B1 (fr) |
FR (1) | FR2874012B1 (fr) |
IL (1) | IL180867A0 (fr) |
MA (1) | MA28847B1 (fr) |
MX (1) | MX2007001383A (fr) |
NO (1) | NO20071209L (fr) |
PE (1) | PE20060419A1 (fr) |
TW (1) | TW200616948A (fr) |
UY (1) | UY29054A1 (fr) |
WO (1) | WO2006024777A1 (fr) |
ZA (1) | ZA200700950B (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2908766A1 (fr) * | 2006-11-20 | 2008-05-23 | Sanofi Aventis Sa | Derives de pyrrole,leur preparation et leur utilisation en therapeutique. |
WO2009141532A2 (fr) | 2008-05-09 | 2009-11-26 | Sanofi-Aventis | Derives de pyrrole, leur preparation et leur application en therapeutique |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1784186A4 (fr) * | 2004-06-16 | 2008-05-14 | Inotek Pharmaceuticals Corp | Methodes de traitement ou de prevention de la dysfonction erectile ou de l'incontinence urinaire |
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
FR2887548B1 (fr) * | 2005-06-27 | 2007-09-21 | Sanofi Aventis Sa | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |
FR2930940B1 (fr) * | 2008-05-09 | 2011-02-11 | Sanofi Aventis | Derives de pyrrole, leur preparation et leur application en therapeutique |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005156A1 (fr) * | 1978-03-13 | 1979-11-14 | E.I. Du Pont De Nemours And Company | 4,5-Diaryl-2-(thio-substitué)-pyrroles et leurs sulfoxydes et sulfones correspondants, procédé pour leur préparation et composition pharmaceutique les contenant |
EP0038536A1 (fr) * | 1980-04-18 | 1981-10-28 | E.I. Du Pont De Nemours And Company | 4,5-Diaryl-alpha-(polyfluoroalkyl)-1H-pyrrole-2-méthanamines anti-inflammatoires |
WO1997019063A1 (fr) * | 1995-11-23 | 1997-05-29 | Sanofi | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
WO2001058869A2 (fr) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
WO2003007887A2 (fr) * | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides |
WO2003042174A1 (fr) * | 2001-11-14 | 2003-05-22 | Schering Corporation | Ligands du recepteur des cannabinoides |
WO2003063781A2 (fr) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Imidazoles substitues en tant que modulateurs du recepteur cannabinoide |
WO2004026301A1 (fr) * | 2002-09-19 | 2004-04-01 | Solvay Pharmaceuticals B.V. | Derives de 1h-1,2,4-triazole-3-carboxamide ayant une activite agoniste partielle, agoniste ou antagoniste inverse du recepteur de cannabinoides-cb1 |
WO2004058249A1 (fr) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Derives de 1,5-diaryl-pyrrole-3-carboxamide et leur utilisation en tant que modulateurs des recepteurs des cannabinoides |
WO2004060870A1 (fr) * | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Nouveaux agonistes inverses du recepteur cb 1 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
WO2003075660A1 (fr) * | 2002-03-06 | 2003-09-18 | Merck & Co., Inc. | Methode de traitement ou de prevention de l'obesite |
US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US6813818B2 (en) | 2002-12-24 | 2004-11-09 | Dana Corporation | Method for joining vehicle frame components |
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
FR2882054B1 (fr) * | 2005-02-17 | 2007-04-13 | Sanofi Aventis Sa | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique |
FR2887548B1 (fr) * | 2005-06-27 | 2007-09-21 | Sanofi Aventis Sa | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |
-
2004
- 2004-08-09 FR FR0408773A patent/FR2874012B1/fr not_active Expired - Fee Related
-
2005
- 2005-08-02 AU AU2005279086A patent/AU2005279086A1/en not_active Abandoned
- 2005-08-02 EA EA200700179A patent/EA012726B1/ru not_active IP Right Cessation
- 2005-08-02 JP JP2007525320A patent/JP2008509202A/ja active Pending
- 2005-08-02 CN CNA2005800302513A patent/CN101014588A/zh active Pending
- 2005-08-02 ZA ZA200700950A patent/ZA200700950B/en unknown
- 2005-08-02 KR KR1020077005467A patent/KR20070054649A/ko not_active Application Discontinuation
- 2005-08-02 BR BRPI0514235-0A patent/BRPI0514235A/pt not_active IP Right Cessation
- 2005-08-02 CA CA002576717A patent/CA2576717A1/fr not_active Abandoned
- 2005-08-02 WO PCT/FR2005/002015 patent/WO2006024777A1/fr active Application Filing
- 2005-08-02 EP EP05796087A patent/EP1781636A1/fr not_active Withdrawn
- 2005-08-02 MX MX2007001383A patent/MX2007001383A/es active IP Right Grant
- 2005-08-05 AR ARP050103275A patent/AR050447A1/es unknown
- 2005-08-05 PE PE2005000908A patent/PE20060419A1/es not_active Application Discontinuation
- 2005-08-08 TW TW094126839A patent/TW200616948A/zh unknown
- 2005-08-08 UY UY29054A patent/UY29054A1/es not_active Application Discontinuation
-
2007
- 2007-01-22 IL IL180867A patent/IL180867A0/en unknown
- 2007-01-22 US US11/625,616 patent/US7381727B2/en not_active Expired - Fee Related
- 2007-03-02 MA MA29732A patent/MA28847B1/fr unknown
- 2007-03-05 NO NO20071209A patent/NO20071209L/no not_active Application Discontinuation
-
2008
- 2008-04-14 US US12/102,412 patent/US7879902B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005156A1 (fr) * | 1978-03-13 | 1979-11-14 | E.I. Du Pont De Nemours And Company | 4,5-Diaryl-2-(thio-substitué)-pyrroles et leurs sulfoxydes et sulfones correspondants, procédé pour leur préparation et composition pharmaceutique les contenant |
EP0038536A1 (fr) * | 1980-04-18 | 1981-10-28 | E.I. Du Pont De Nemours And Company | 4,5-Diaryl-alpha-(polyfluoroalkyl)-1H-pyrrole-2-méthanamines anti-inflammatoires |
WO1997019063A1 (fr) * | 1995-11-23 | 1997-05-29 | Sanofi | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
WO2001058869A2 (fr) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires |
WO2003007887A2 (fr) * | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides |
WO2003042174A1 (fr) * | 2001-11-14 | 2003-05-22 | Schering Corporation | Ligands du recepteur des cannabinoides |
WO2003063781A2 (fr) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Imidazoles substitues en tant que modulateurs du recepteur cannabinoide |
WO2004026301A1 (fr) * | 2002-09-19 | 2004-04-01 | Solvay Pharmaceuticals B.V. | Derives de 1h-1,2,4-triazole-3-carboxamide ayant une activite agoniste partielle, agoniste ou antagoniste inverse du recepteur de cannabinoides-cb1 |
WO2004058249A1 (fr) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Derives de 1,5-diaryl-pyrrole-3-carboxamide et leur utilisation en tant que modulateurs des recepteurs des cannabinoides |
WO2004060870A1 (fr) * | 2003-01-02 | 2004-07-22 | F. Hoffmann-La Roche Ag | Nouveaux agonistes inverses du recepteur cb 1 |
Non-Patent Citations (5)
Title |
---|
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HAUPTMANN, S. ET AL: "Reactions of 2-aminovinylcarbonyl compounds", XP002358736, retrieved from STN Database accession no. 1972:551789 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HEMETSBERGER, HELFRIED ET AL: "Synthesis and thermolysis of .alpha.-azido-.alpha.,.gamma.-dienoic esters", XP002321703, retrieved from STN Database accession no. 1978:22311 * |
HANDY, SCOTT T. ET AL: "An unusual dehalogenation in the Suzuki coupling of 4-bromopyrrole-2-carboxylates", TETRAHEDRON LETTERS, vol. 44, no. 3, 2003, pages 427 - 430, XP002321702 * |
JOURNAL FUER PRAKTISCHE CHEMIE (LEIPZIG) , 314 (2), 353 -64 CODEN: JPCEAO; ISSN: 0021-8383, 1972 * |
JOURNAL OF CHEMICAL RESEARCH, SYNOPSES, vol. 10, 1977, pages 247 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2908766A1 (fr) * | 2006-11-20 | 2008-05-23 | Sanofi Aventis Sa | Derives de pyrrole,leur preparation et leur utilisation en therapeutique. |
WO2008068423A2 (fr) | 2006-11-20 | 2008-06-12 | Sanofi-Aventis | Derives de pyrrole, leur preparation et leur utilisation en therapeutique. |
WO2008068423A3 (fr) * | 2006-11-20 | 2008-07-31 | Sanofi Aventis | Derives de pyrrole, leur preparation et leur utilisation en therapeutique. |
JP2010510198A (ja) * | 2006-11-20 | 2010-04-02 | サノフイ−アベンテイス | ピロール誘導体、この調製および治療における使用 |
US8044072B2 (en) | 2006-11-20 | 2011-10-25 | Sanofi Aventis | Pyrrole derivatives, preparation thereof and therapeutic use thereof |
WO2009141532A2 (fr) | 2008-05-09 | 2009-11-26 | Sanofi-Aventis | Derives de pyrrole, leur preparation et leur application en therapeutique |
Also Published As
Publication number | Publication date |
---|---|
KR20070054649A (ko) | 2007-05-29 |
MX2007001383A (es) | 2007-04-19 |
AU2005279086A1 (en) | 2006-03-09 |
TW200616948A (en) | 2006-06-01 |
US20070149596A1 (en) | 2007-06-28 |
CA2576717A1 (fr) | 2006-03-09 |
ZA200700950B (en) | 2008-06-25 |
FR2874012A1 (fr) | 2006-02-10 |
FR2874012B1 (fr) | 2008-08-22 |
IL180867A0 (en) | 2007-07-04 |
NO20071209L (no) | 2007-03-05 |
MA28847B1 (fr) | 2007-09-03 |
BRPI0514235A (pt) | 2008-06-03 |
US7381727B2 (en) | 2008-06-03 |
PE20060419A1 (es) | 2006-06-20 |
CN101014588A (zh) | 2007-08-08 |
EA012726B1 (ru) | 2009-12-30 |
EP1781636A1 (fr) | 2007-05-09 |
EA200700179A1 (ru) | 2007-08-31 |
AR050447A1 (es) | 2006-10-25 |
US7879902B2 (en) | 2011-02-01 |
UY29054A1 (es) | 2006-03-31 |
US20080194581A1 (en) | 2008-08-14 |
JP2008509202A (ja) | 2008-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1853557A2 (fr) | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
EP1716142A2 (fr) | Derives d'oxazole, leur preparation et leur utilisation en therapeutique | |
WO2005000817A2 (fr) | Derives de diphenylpyridine, leur preparation et leur application en therapeutique | |
EP1781636A1 (fr) | Derives de pyrrole, leur preparation et leur utilisation en therapeutique | |
EP1899298B1 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
EP2094656B1 (fr) | Derives de pyrrole, leur preparation et leur utilisation en therapeutique. | |
WO2006042955A1 (fr) | Derives de pyridine, leur preparation, leur application en therapeutique | |
FR2860792A1 (fr) | Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique | |
EP2283007A2 (fr) | Dérivés de 1,5-diphénylepyrrole-3-carboxamide, leur preparation et leur utilisation comme antagonistes des récepteurs cb1 des cannabinoïdes | |
WO2008099076A2 (fr) | Derives de n-(4-cyano-l h-p yrazol-3 -yl)methylamine substitues, leur preparation et leur application en therapeutique | |
FR2930940A1 (fr) | Derives de pyrrole, leur preparation et leur application en therapeutique | |
MX2007009648A (en) | 1,5-diarylpyrrole derivatives, preparation method thereof and application of same in therapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 180867 Country of ref document: IL Ref document number: 11625616 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2576717 Country of ref document: CA Ref document number: 200700179 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 337/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007/00950 Country of ref document: ZA Ref document number: 200700950 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/001383 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500307 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2007000095 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007525320 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07013177 Country of ref document: CO |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 553537 Country of ref document: NZ Ref document number: 2005279086 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005796087 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077005467 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580030251.3 Country of ref document: CN Ref document number: 1200700530 Country of ref document: VN |
|
ENP | Entry into the national phase |
Ref document number: 2005279086 Country of ref document: AU Date of ref document: 20050802 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005279086 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005796087 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11625616 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0514235 Country of ref document: BR |